Of note, the treatment of the cells with two EPHB4 inhibitors, JI‐101 and NVP‐BHG712, was able to rescue the phenotype driven by the variant suggesting that EPHB4 is a promising therapeutic target in high‐risk NB. This evidence concerns the gene EPHB4 and neuroblastoma.